Pain Management Drugs Market : Alleviating Pain, Maximizing Comfort Set to Soar to $91.6 Billion by 2027 | CAGR 3.8%
According to a new report published by Allied Market Research, titled, “Pain Management Drug Market by drug class, indication, and pain type: opportunity analysis and industry forecast, 2019–2027”. The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million by 2027, registering a CAGR of 3.8%
𝐏𝐚𝐢𝐧 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭
𝐂𝐥𝐢𝐜𝐤 𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 @ https://www.alliedmarketresearch.com/request-sample/404
- The global pain management market is majorly driven by surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis. Furthermore, rise in number of surgical procedures and surge in healthcare expenditure are expected to fuel growth of the market
- Pain is a complex medical condition, which not only affects physical but also mental well-being of an individual. It is caused due to trauma or tissue damage, and its intensity varies from person to person. Pain control medications help to alleviate pain through various pathways in patient’s body.
- There are various types of medicines available in the pain management drugs market targeting specific biomolecules in the body and manipulating specific mechanisms to avoid pain sensation. On the basis of cause of pain, the treatment provided can be simple or complex. Pain can be managed using a variety of pharmacological and non-pharmacological therapies.
The Pain Management Market statistics-
- As per statistics provided by the UN Population Division, in 2019, total proportion of people above 65 years has increased from 703 million in 2019 and is projected to reach 1.5 billion by 2050, globally.
- Increase in R&D investments and rise in outsourcing of pharmaceuticals are expected to fuel the market growth in developing regions such as Asia-Pacific and LAMEA. However, availability of alternative therapies and patent expiration of prescription drugs for treatment of pain hamper growth of the pain management drugs market.
𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲? 𝐀𝐬𝐤 𝐎𝐮𝐫 𝐄𝐱𝐩𝐞𝐫𝐭 @ https://www.alliedmarketresearch.com/pain-management-therapeutics-market/purchase-options
The Pain Management Market segment-
The opioids segment was the largest contributor to the market growth in 2019, opioids segment is the largest contributor toward the market growth, owing to high popularity of these drugs worldwide.
- The anesthetics segment is anticipated to be the fastest growing segment in the market, owing to frequent use of this drug type during surgeries and rise in number of surgeries globally.
- Neuropathic Pain segment accounted for a majority of the pain management drugs market share in 2019 and is expected to exhibit a prominent growth rate during the forecast period, increase in presence of large patient population is the major factor that increases the demand for drugs for neuropathic pain.
- Cancer pain and chronic back pain were segment is expected to grow at the highest rate throughout the forecast period in 2019, owing to increase in number of surgeries globally and rise in prevalence of chronic diseases that lead to back pain.
𝐎𝐧 𝐭𝐡𝐞 𝐛𝐚𝐬𝐢𝐬 𝐨𝐟 𝐩𝐚𝐢𝐧 𝐭𝐲𝐩𝐞, 𝐭𝐡𝐞 𝐜𝐡𝐫𝐨𝐧𝐢𝐜 𝐩𝐚𝐢𝐧 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐰𝐚𝐬 𝐭𝐡𝐞 𝐥𝐚𝐫𝐠𝐞𝐬𝐭 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐨𝐫 𝐭𝐨 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝟐𝟎𝟏𝟗, 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟑.𝟗% 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝 𝟐𝟎𝟐𝟕.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐚 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.alliedmarketresearch.com/checkout-final/48e8a41468d761e443dfbc736910f734
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐑𝐞𝐯𝐢𝐞𝐰
The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market.
However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.
Employment of pain management drugs is the highest in North America, owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth.
Although the use of pain management drugs in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and surge in incidences of chronic diseases. China and India are potential markets in Asia-Pacific. Moreover, increase in R&D investments, upsurge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in Asia-Pacific.
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Editor Details
-
Company:
- The Wire Times
